Knowledge of remote medication abortion among patients traveling from states that restrict abortion
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Oct-2026 20:16 ET (26-Oct-2026 00:16 GMT/UTC)
A pair of wearable stickers may transform diagnostic sweat testing for cystic fibrosis (CF), a genetic disorder that causes problems with digestion and breathing. The innovative technology was found to be reliably accurate compared to standard sweat testing, according to the study published in npj Digital Medicine journal.
Transgender and gender diverse (TGD) individuals experience significant healthcare disparities across the oncology spectrum of care. Systemic barriers, past harmful healthcare experiences and sociopolitical climate, and other impediments to accessing health care among others, combine to influence these disparities. TGD individuals undergoing gender-affirming mastectomy (‘top surgery’) face unique challenges related to breast cancer risk assessment and screening. Currently, a patient can undergo top surgery without understanding how that procedure will affect their lifelong breast and chest cancer risk – and critically, without knowing if they carry predispositions that could fundamentally reshape their surgical decisions.
A new study by researchers at Boston University Chobanian & Avedisian School of Medicine has identified critical barriers that influence healthcare professionals' integration of cancer risk evaluation, within the context of gender-affirming mastectomy and pre-surgical planning. They include clear institutional accountability, harmonized evidence-based guidelines, standardized care pathways and embedded genetic counseling in multidisciplinary gender-affirming care teams. These findings mirror what patients reported in a previous companion study – that they lack clear information before and after surgery.
Insilico Medicine (“Insilico”, HKEX:3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of the Drug Discovery and Development (DDD) Benchmarks as a Service (BaaS). It is a pioneering standardized evaluation framework anchored in carefully decontaminated real-world data and proprietary validated programs. for measuring how frontier AI and foundation models built on other architectures perform on real-world tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research.